Veklury Archives -

Eli Lilly and Incyte’s JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients

Olumiant benefits additive to other drugs in severe COVID patients

https://pharmaphorum.com/news/olumiant-benefits-additive-to-other-drugs-in-severe-covid-patients/

The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with

FDA clears Gilead’s Veklury for COVID outpatients

https://pharmaphorum.com/news/fda-clears-gileads-veklury-for-covid-outpatients/

Gilead Sciences says its antiviral Veklury should be effective against the new, more contagious COVID-19 variants discovered in

Gilead says Veklury should work against COVID-19 variants

https://pharmaphorum.com/news/gilead-says-veklury-should-work-against-covid-19-variants/

Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment

Gilead Q3 revenue rise bolstered by $873m Veklury sales

https://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/

US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury

BioSig abandons COVID-19 drug trial on safety concerns

https://pharmaphorum.com/news/biosig-abandons-covid-19-drug-trial-on-safety-concerns/

Gilead’s Veklury (remdesivir) has become the first COVID-19 drug approved in the US following a nod from the

Gilead’s remdesivir finally gets US approval

https://pharmaphorum.com/news/gileads-remdesivir-finally-gets-us-approval/

Veklury